Blake Simmons
Optometrist · Colorado Springs, CONPI 1003909482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 117 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$573
- Novartis$326
- Alcon$201
- AbbVie$172
- Mallinckrodt Hospital Products Inc.$162
- Bausch & Lomb Americas Inc.$148
- plus $815 from 19 others
Across 25 payments — averaging $16,586 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$216K
- Novartis$71K
- Dompe Farmaceutici S.p.a.$48K
- Aerie Pharmaceuticals, Inc.$41K
- Alcon Research LLC$37K
What the payments were for
- Food & beverage$2,35298%
- Education$90%
- Entertainment$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 22 | $573 |
| Novartis | 19 | $326 |
| Alcon | 9 | $201 |
| AbbVie(2 entities) | 10 | $172 |
| Mallinckrodt Hospital Products Inc. | 7 | $162 |
| Bausch & Lomb Americas Inc. | 7 | $148 |
| Aerie Pharmaceuticals, Inc. | 6 | $110 |
| Oyster Point Pharma, Inc. | 5 | $100 |
| Tarsus Pharmaceuticals, Inc. | 3 | $80 |
| Kala Pharmaceuticals, Inc. | 4 | $71 |
| Dompe US, Inc. | 3 | $53 |
| Eyevance Pharmaceuticals LLC | 3 | $49 |
| Shire North American Group Inc | 2 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $42 |
| Rxsight Inc | 1 | $38 |
| Optos, Inc. | 1 | $36 |
| Biotissue Holdings Inc. | 2 | $35 |
| Coopervision Inc. | 2 | $34 |
| Johnson & Johnson Vision Care, Inc. | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Harrow Eye, LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $9 |
How this compares
$2,397 in reported general payments places this provider in the 80th percentile of 1,025 optometrist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 45 | $83,275 |
| RestasisCyclosporine | 34 | $46,705 |
| XiidraLifitegrast | 24 | $38,491 |
| LumiganBimatoprost | 31 | $18,913 |
| CequaCyclosporine | 16 | $18,670 |
| RhopressaNetarsudil Mesylate | 16 | $10,814 |
| EysuvisLoteprednol Etabonate | 14 | $7,571 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $6,137 |
| Fluorometholone | 36 | $4,191 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,003 |
| Travoprost | 17 | $3,189 |
| Prednisolone Acetate | 48 | $2,737 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,367 |
| Latanoprost | 96 | $932 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $80 | $83,27545 claims |
| AbbVieRestasis, Lumigan, Combigan | $172 | $69,62077 claims |
| Bausch & Lomb Americas Inc.Xiidra | $148 | $38,49124 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $573 | $18,67016 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $110 | $10,81416 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $71 | $7,57114 claims |
| AlconSimbrinza | $201 | $6,13722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,025 optometrist providers in Colorado.
Other optometrist in Colorado Springs
- Justin ManningColorado Springs$13K
- Melissa TadaColorado Springs$9K
- Reed BroColorado Springs$8K
- Minon MitchellColorado Springs$8K
- Ryan BauerColorado Springs$6K
- Shane FrerichsColorado Springs$5K
- Leroy PopowskiColorado Springs$5K
- Cecelia KoettingAurora$458K
- Kaleb AbbottAurora$145K
- Joshua OlsonBoulder$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.